2001;37:529 33. S7.1.3-17. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.1.3-18. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ven- tricular tachycardia burden and ICD shocks in patients with drug- refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600 6. S7.1.3-19. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250 9. S7.1.3-20. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77 82. S7.1.3-21. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227 33. S7.1.3-22. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.1.3-23. Sears SE Jr, Conti JB, Understanding implantable cardioverter defi- brillator shocks and storms: medical and psychosocial consider- ations for research and clinical care. Clin Cardiol. 2003;26:107 11. S7.1.3-24. Sweeney MO, Sherfesee L, Degroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7:353 60. S7.1.3-25. Berntsen RF, Gunnes P, Lie M, et al. Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia. Eur Heart J. 1993;14:1297 303. S7.1.3-26. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/ SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016;32:1 28. 7.2. Nonischemic Cardiomyopathy S7.2-1. 